<DOC>
	<DOCNO>NCT00571324</DOCNO>
	<brief_summary>The purpose study determine Exendin- ( 9-39 ) , antagonist glucagon-like peptide-1 ( GLP-1 ) receptor effect pancreatic beta cell , increase fast blood glucose level subject congenital hyperinsulinism .</brief_summary>
	<brief_title>Effect Exendin- ( 9-39 ) Glycemic Control Subjects With Congenital Hyperinsulinism</brief_title>
	<detailed_description>This open-label , pilot study , determine Exendin- ( 9-39 ) , antagonist glucagon-like peptide-1 ( GLP-1 ) receptor effect pancreatic beta cell , increase fast blood glucose level subject congenital hyperinsulinism . Our overall hypothesis abnormal GLP-1 secretion result dysfunctional nutrient sense intestinal L-cells play role dysregulated insulin secretion characteristic disorder , antagonism GLP-1 receptor increase fast blood glucose level . Aim 1 . To evaluate dose exendin- ( 9-39 ) require elevate fasting blood glucose level subject congenital hyperinsulinism due KATP channel mutation . Aim 2 . To determine therapeutic plasma level , plasma half-life pharmacokinetics exendin- ( 9-39 ) intravenous short-term infusion subject congenital hyperinsulinism due Adenosine triphosphate ( ATP ) -sensitive potassium channel ( KATP ) mutation .</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subjects congenital hyperinsulinism Acute medical illness History systemic chronic disease cardiac failure , renal insufficiency , hepatic insufficiency , chronic obstructive pulmonary disease , anemia , uncontrolled hypertension Pregnancy Diabetes mellitus Use medication affect glucose metabolism , glucocorticoid , beta agonist , diazoxide octreotide . Subjects eligible participate 48 hr last dose octreotide 72 hr last dose diazoxide</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hyperinsulinism</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>KATP channel</keyword>
	<keyword>Kir6.2</keyword>
</DOC>